Short answer
Inogen Inc (INGN) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $53M (down 42.7% year over year) with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $53M
- −42.7% YoY · −44.3% QoQ
- Net income
- −$16M
- −205.2% YoY · −319.6% QoQ
- Operating margin
- -26.5%
- Gross margin
- 44.7%
- EPS (diluted)
- −$0.60
- −215.8% YoY · −300.0% QoQ
Source: XBRL data from the Inogen Inc (INGN) Q3 2026 10-Q on SEC EDGAR. USD.
Inogen Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $77.2M, down 2.4% YoY from $79.1M, with U.S. sales up 3.8% and international sales down 9.0%
- Gross margin 44.1% vs 45.7% YoY; continuing-operations loss $14.8M vs $3.6M, including $10.6M goodwill impairment
- Best market: U.S. sales $42.2M, up 3.8%; weakest: international sales $34.9M, down 9.0%
- Cash $81.8M plus marketable securities $15.0M; operating cash use $13.6M through nine months, share repurchases $11.2M
- Rental-business sale up to $24.8M; cost program targeting $20M annualized savings, with supply-chain, inflation, geopolitical, and freight headwinds
Risk Factors
- New divestiture risk triggered by November 2 Rental Business sale: Rotech consideration up to $24.8 million payable in six installments
- Regulatory and compliance risk: patient transfers require HIPAA, state privacy, and payor compliance
- Operational risk: Rental Business revenue of $35.6 million eliminated, increasing dependence on product sales
- Cost-reduction risk triggered by November 5 program: approximately $20 million annualized savings may not materialize
- Financial risk: retained Rental Business liabilities include potential Medicare, Medicaid, and payor recoupment demands
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inogen Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.